Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced that the US Food and Drug Administration (FDA) has approved Tradjenta (linagliptin), a dipeptidyl peptidase-4 inhibitor used to lower blood sugar in adults with type 2 diabetes.
Tradjenta can be used as monotherapy or in combination with metformin, sulfonylurea or pioglitazone.
When used as monotherapy, Tradjenta showed significant A1C reductions of up to 0.7%, and reductions of 0.5% when used in combination with pioglitazone.
Adverse affects observed with the use of the drug include nasopharyngitis, hypoglycaemia, and pancreatitis.
Tradjenta is under regulatory review in the EU and Japan.
Share this article
